---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-260795"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2023-10-23T23:59:59+00:00"
generated_at: "2026-06-09T17:04:34.519973+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ORIC-114 Phase 1 data shows first confirmed CNS complete response in EGFR exon 20 NSCLC

## Summary
- 81% of EGFR exon 20 NSCLC patients had prior exon 20 targeted agents; 86% had CNS metastases at baseline.
- At 75 mg QD (potential RP2D): 67% unconfirmed ORR and 33% confirmed ORR in post-amivantamab patients (n=3).
- First confirmed CNS complete response reported by an EGFR exon 20 inhibitor in untreated brain metastases.
- HER2 exon 20 patients: partial responses observed, including 100% target lesion regression.
- Favorable safety: mostly Grade 1-2 TRAEs; no Grade 3+ rash; 4% discontinuations; MTD not reached.

## SEC filing metadata
- accession: 0001193125-23-260795
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2023-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000119312523260795/0001193125-23-260795-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000119312523260795/d561418d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-260795
- JSON: https://secwatch.observer/filing/0001193125-23-260795.json
- Plain text: https://secwatch.observer/filing/0001193125-23-260795.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.